Already have an account? Sign in.
Fortress Biotech Stock Plummets After FDA Rejection
FDA rejected Fortress Biotech's Menkes drug, CUTX-101, due to factory issues, but the drug's safety and efficacy data were fine.
FDA rejected Fortress Biotech's Menkes drug, CUTX-101, due to factory issues, but the drug's safety and efficacy data were fine.
Accenture and Anthropic will embed evaluators inside Anthropic to test models, red-team risks, and check safeguards. Each plans $1B over 5 years.
New Era Energy (NUAI) rose after signing a 20-year PPA with a Vistra affiliate for up to 207 MW to power Phase 1 of its Texas data center.
Priority Technology Holdings agrees to a $1.6 billion take-private deal led by CEO Thomas Priore at $8.05 per share, representing a 38% premium. The deal is expected to close in the first half of 2027.